Table 2.
Time to event analysis.
| Before PSM | After PSM | |||
|---|---|---|---|---|
| Non-IC/BPS | IC/BPS | Control | IC/BPS | |
| n = 21 900 | n = 1,095 | n = 4,224 | n = 1,056 | |
| Follow up person months | 1,654,806 | 79,147 | 312,164 | 76,839 |
| Event of ADs | 1,373 | 105 | 287 | 102 |
| Incidence rate* (95% CI) | 8.30 (7.87–8.75) | 13.27 (10.96–16.06) | 9.19 (8.19–10.32) | 13.27 (10.93–16.12) |
| Model 1: Crude hazard ratio (95% CI) | Reference | 1.595 (1.308–1.945) | Reference | 1.442 (1.151–1.808) |
per 10,000 person-months.
IC/BPS, interstitial cystitis/bladder pain syndrome; ADs, autoimmune diseases; PSM, propensity score matching; CI, confidence interval.